Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1075-1080
Published online before print May 23, 2002, doi: 10.1161/01.ATV.0000022695.22369.BE
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
22/7/1075    most recent
01.ATV.0000022695.22369.BEv1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tiran, A.
Right arrow Articles by Tiran, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tiran, A.
Right arrow Articles by Tiran, B.
Related Collections
Right arrow Pathophysiology
Right arrow Growth factors/cytokines
Right arrow Physiological and pathological control of gene expression
Right arrow Mechanism of atherosclerosis/growth factors
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1075.)
© 2002 American Heart Association, Inc.


Vascular Biology

Aspirin Inhibits Chlamydia pneumoniae–Induced Nuclear Factor-{kappa}B Activation, Cytokine Expression, and Bacterial Development in Human Endothelial Cells

Andreas Tiran; Hans-Jürgen Gruber; Wolfgang F. Graier; Andreas H. Wagner; Ellen B.M. van Leeuwen; Beate Tiran

From the Department of Laboratory Medicine (A.T., H-J.G., B.T) and the Institute of Medical Biochemistry and Medical Molecular Biology (W.F.G.), University of Graz, Graz, Austria; the Department of Cardiovascular Physiology (A.H.W.), University of Goettingen, Goettingen, Germany; and the Department of Haematology (E.B.M.v.L.), University of Groningen, Groningen, the Netherlands.

Correspondence to Andreas Tiran, Department of Laboratory Medicine, University of Graz, Auenbruggerplatz 15, A-8036 Graz, Austria. E-mail andreas.tiran{at}uni-graz.at

Objective Chlamydia pneumoniae has been associated with atherosclerosis. Infection of vascular endothelial cells with C pneumoniae increases the expression of proatherogenic cytokines mediated by nuclear factor (NF)-{kappa}B, a transcription factor. The present study was designed to test the effect of aspirin on C pneumoniae–induced NF-{kappa}B activation, interleukin expression, and bacterial development in cultured human endothelial cells.

Methods and Results Aspirin, its metabolite salicylic acid, and 2 other unrelated NF-{kappa}B inhibitors showed a strong concentration-dependent inhibitory effect on chlamydial growth, indicated by the reduction of bacterial inclusions and the titer of infectious progeny. Involvement of the transcription factor NF-{kappa}B was confirmed by electrophoretic mobility shift assay and by transfection experiments with appropriate decoy oligodeoxynucleotides. Attenuation of the C pneumoniae–induced activation of NF-{kappa}B by aspirin also reduced the secretion of interleukin-6 and interleukin-8, indicating efficient inhibition of NF-{kappa}B gene expression. Reduction of chlamydial growth was not caused by apoptosis of the host cell, as determined by monitoring characteristic chromatin condensation.

Conclusions These data provide evidence that NF-{kappa}B–mediated gene activation represents a crucial step in the developmental cycle of C pneumoniae. Aspirin exerts an anti-chlamydial effect that is due to the inhibition of C pneumoniae–induced NF-{kappa}B activation, which might account for some of the cardioprotective activity of aspirin.


Key Words: aspirin • transcription factor • Chlamydia pneumoniae • nuclear factor-{kappa}B




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
D. J. Schneider
On Defining Aspirin Resistance
J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1710 - 1711.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
X. Yang, D. Coriolan, K. Schultz, D. T. Golenbock, and D. Beasley
Toll-Like Receptor 2 Mediates Persistent Chemokine Release by Chlamydia pneumoniae-Infected Vascular Smooth Muscle Cells
Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): 2308 - 2314.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. J. Lindsberg and A. J. Grau
Inflammation and Infections as Risk Factors for Ischemic Stroke
Stroke, October 1, 2003; 34(10): 2518 - 2532.
[Abstract] [Full Text] [PDF]


Home page
J Med MicrobiolHome page
H. Yoneda, K. Miura, H. Matsushima, K. Sugi, T. Murakami, K. Ouchi, K. Yamashita, H. Itoh, T. Nakazawa, M. Suzuki, et al.
Aspirin inhibits Chlamydia pneumoniae-induced NF-{kappa}B activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth
J. Med. Microbiol., May 1, 2003; 52(5): 409 - 415.
[Abstract] [Full Text] [PDF]